Information on APRILD

Basic details

Name: APRIL deficiency | Acronym: APRILD
Alt. names: Autosomal recessive TNFSF13 loss-of-function

Gene: TNFSF13 | MOI: Autosomal recessive | Mechanism of action: Loss of Function

No. of cases in DB: 1 | First reported in: 2020

Last updated on: 2023-10-22 21:20:16 by Xiao P. Peng

OMIM:

Orphanet: -

MONDO: -

DOID: -

ClinGen:

Description

Only 1 patient has been reported in the literature thus far - Yeh et al. (2020) identified a a nullomorphic homozygous TNFSF13 frameshift mutation in a 55-year-old Japanese man presenting with history of mild sinorespiratory infections, steroid-responsive alopecia areata and later development of small lung nodules. On labs, he had incidentally found, progressive hypogammaglobulinemia and reduced memory B cells, but normal overall T- and B-cell counts and proliferative responses (PMID: 32298700).

Management

For his humoral immunodeficiency, the above patient was started and maintained on lifetime immunoglobulin replacement, beginning with intravenous and then later switching to subcutaneous administration - this appeared to improve his infection susceptibility (PMID: 32298700). His alopecia areata was successfully treated with prednisolone for 3 months. His sinorespiratory infections were treated with antibiotics as needed. No other forms of management have been discussed in the literature.

1 reported cases added to GenIA

SubjectID Sex Fam.ID AD AFM Validity Country Population Reference & Pub.code
102530arrow icon M 214966tree icon 55 11 Japan Japanese PMID:32298700 [Patient(V.3)]

AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).

Summary of clinical findings

[Considering only Definitive and Possible cases]

Rank Clinical term Present Absent Unreported
1 Decreased IgA levelsarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
2 Increased proportion of marginal zone B cellsarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
3 Sinusitisarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
4 Otitis mediaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
5 Decreased IgG levelsarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
6 Pulmonary nodulearrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
7 (unusual) Respiratory tract infectionarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
8 Decreased IgM levelsarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
9 Alopecia areataarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
10 Hypogammaglobulinemiaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
11 Bronchitisarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
12 Increased IgE levelsarrow icon 0 (0.0%) 1 (99.9%) 0 (0.0%)

Summary of treatment outcomes

[Considering only Definitive and Possible cases]

Treatment ⓘ Responses & clinical indications